BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

CVRx (CVRX)CVRxClinical readout

Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is Supported by CMS Category B IDE Coverage MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and

Open original release

Related news

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

CVRXCVRx2026-05-14 12:00 EST

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

ANGOAngioDynamics2026-05-13 13:00 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

BSXBoston Scientific2026-05-19 10:31 EST

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

MLYSMineralys Therapeutics2026-05-30 15:15 EST

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

MLYSMineralys Therapeutics2026-05-18 20:05 EST

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

View all latest news

CVRx

CVRx is a medical device company focused on neuromodulation therapies for heart failure and hypertension-related conditions. Its products aim to address cardiovascular disease through implanted device technology.

Recent company news

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRXCVRx2026-05-14 12:00 EST

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Stock data

Close
4.88 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States